Skip to main content

Table 1 Polysomnograph results in a patient with Prader-Willi syndrome and narcoleptic and cataplectic symptoms 1

From: Prader-Willi syndrome, excessive daytime sleepiness, and narcoleptic symptoms: a case report

 

2y 10mo

5y 3mo

6y 10mo

8y 5mo

9y 3mo

Sleep architecture

Total sleep time (min)

420.5

489.5

516.5

520

492

Sleep efficiency (%)

84.9

90.8

92.7

94.4

95.1

Sleep stages total sleep time

Stage 1 (%)

6.5

2.2

2.5

0.6

2.1

Stage 2 (%)

43.4

48.1

57.9

64.7

59.3

Stage 3 and 4 (%)

22.5

25.8

18.6

18

18.5

REM (%)

27.6

23.9

21.0

16.8

20.1

Apnea events

Central apnea index (events per hour)

0.57

0

0.46

2.08

2.32

Obstructive apnea index (events per hour)

0.14

0.12

0

0.12

0

Number of mixed events per hour

0.43

0

0.58

0

0

Hypopnea events (events per hour)

0.29

0.25

0.23

0.34

3.05

Apnea-hypopnea index (events per hour)

1.4

0.4

1.3

2.7

5.6

End-tidal carbon dioxide (ETCO2)

Mean total recorded ETCO2 (mmHg)

44.5

46

42

43

45

Maximum total recorded ETCO2 (mmHg)

60.9

60

51

50

54

Oxygen saturation (SaO2)

Mean total recorded SaO2 (%)

94.1

95

97

94

96

Minimum total recorded SaO2 (%)

78.7

87

88

84

84

Anthropometrics

Height (cm)

84

97

104

110

116

Weight (kg)

11.25

15.2

17.4

20.0

21.4

BMI- z score

0.12

0.66

0.39

0.25

−0.23

  1. 1Modafinil therapy was initiated at age seven years six months; growth hormone therapy was initiated at age eight years eight months. REM, rapid eye movement; BMI body mass index.